Nitrosamines in Pharmaceuticals: Regulatory Requirements, Risk Assessment & Testing
Introduction Nitrosamine impurities are a class of potentially carcinogenic impurities that can be present in pharmaceutical products or form during […]
Introduction Nitrosamine impurities are a class of potentially carcinogenic impurities that can be present in pharmaceutical products or form during […]
Introduction The European Commission has published Commission Regulation (EU) 2026/215, introducing amendments to the Maximum Residue Levels (MRLs) for three